Details for Patent: 7,645,459
✉ Email this page to a colleague
Which drugs does patent 7,645,459 protect, and when does it expire?
Patent 7,645,459 protects ATELVIA and is included in one NDA.
This patent has eighty-four patent family members in thirty-three countries.
Summary for Patent: 7,645,459
Title: | Dosage forms of bisphosphonates |
Abstract: | Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. |
Inventor(s): | Dansereau; Richard John (Cilncinnati, OH), Burgio, Jr.; David Ernest (Liberty Township, OH) |
Assignee: | The Procter & Gamble Company (Cincinnati, OH) |
Application Number: | 11/106,816 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,645,459 |
Patent Claim Types: see list of patent claims | Compound; Dosage form; Delivery; Use; |
Drugs Protected by US Patent 7,645,459
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apil | ATELVIA | risedronate sodium | TABLET, DELAYED RELEASE;ORAL | 022560-001 | Oct 8, 2010 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,645,459
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 049022 | ⤷ Try a Trial | |||
Argentina | 098686 | ⤷ Try a Trial | |||
Austria | E475412 | ⤷ Try a Trial | |||
Australia | 2005247299 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |